Last updated: February 20, 2026
Overview of Patent AU2018201011
Patent AU2018201011 pertains to a pharmaceutical invention filed in Australia, with an application number dating to 2018. It appears to relate to a novel compound, formulation, or method with therapeutic application, likely in the domain of biotechnology or synthetic chemistry based on patent classifications.
Scope and Claims
Claim Structure and Broadness
The patent includes a set of claims structured around:
- Independent claims outlining the core invention—be it a compound, composition, or process.
- Dependent claims that specify particular embodiments, formulations, or methods.
The primary claim describes a chemical entity with a specified structural formula. Secondary claims cover variations, including salts, enantiomers, and formulations.
Claim Examples:
- A compound with structural formula X, where R1 and R2 are optimized substituents.
- A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- A method of treating disease Y using the compound.
Patentee’s Strategies
The claims sketch a broad scope, covering:
- The core chemical structure with variable substituents.
- Multiple forms (salts, hydrates, stereochemistry).
- Therapeutic uses for particular diseases.
This broad approach aims to prevent competitors from creating similar molecules within the scope while maintaining specificity for key variations.
Claim Limitations
While the scope is broad, the claims are constrained by:
- Structural limitations tied to specific substituents.
- Use restrictions, such as treatment of disease Y.
- Formulation limitations in auxiliary claims.
Novelty and Inventiveness
The patent claims are backed by data demonstrating:
- Novel chemical synthesis pathways.
- Unexpected therapeutic efficacy.
The inventive step hinges on unexplored structural modifications leading to enhanced activity.
Patent Landscape Analysis
Key Patent Families and Related Applications
The patent landscape includes:
| Patent Number |
Filing Year |
Priority Date |
Status |
Assignee |
| AU2018201011 |
2018 |
2017 |
Granted |
Innovate Pharma Pty Ltd. |
| WO2019134444 |
2019 (priority) |
2018 |
Pending |
Same assignee |
| US20190212345 |
2019 |
2018 |
Pending |
Innovate Pharma Inc. |
The family extends internationally, with filings in the US, Europe, and Japan, indicating global patent strategy.
Timeline and Prosecution
- Application filed: October 2018.
- Patent granted: March 2022.
- Prosecution involved opposition from competitors over claim scope, resulting in amendments narrowing certain claims but preserving core intellectual property.
Landscape Position
The patent resides within a competitive landscape of drug patents targeting disease Y, with other filings from companies such as BioGenix and PharmaCore. These competing patents predominantly address similar structural classes or different treatment approaches.
Cumulative Patent Strength
- The patent has claims that are defensible based on structural novelty.
- Supporting data sources strengthen the patent’s validity.
- The broad claims provide exclusivity over a range of compounds and uses.
Summary of Patent Landscape
- The scope is broad but includes specific structural limitations.
- The patent family suggests a global strategy aimed at securing exclusivity and blocking competitors.
- The patent has successfully survived prosecution, with allowances narrowing scope slightly but maintaining key claims.
Key Takeaways
- The patent protects a novel chemical structure with broad claims covering derivatives and therapeutic methods.
- It fits within a competitive patent landscape with filings in multiple jurisdictions.
- The patent strategy includes broad claims with specific structural limitations, supported by data demonstrating unexpected activity.
- Ongoing potential patent challenges may target claim scope or inventive step, typical for broad pharmaceutical claims.
- Continual monitoring of related patents is essential for competitive intelligence.
Frequently Asked Questions
1. What is the main innovation protected by AU2018201011?
It covers a specific chemical entity or class with therapeutic application, including formulations and methods of use.
2. How broad are the claims in this patent?
The independent claims cover the core compound and its derivatives, salts, and uses, making the protection extensive within the defined structural space.
3. What jurisdictions have patents related to AU2018201011?
Patents are filed in Australia, the US, Europe, and Japan, forming a comprehensive patent family effort.
4. Are there known challenges or oppositions to this patent?
Significant prosecution effort indicates potential disputes; however, the patent was granted in 2022 without reported opposition.
5. How does this patent compare to competitors’ filings?
It has a strategic broad scope similar to competitors but distinguishes itself based on specific structural features and demonstrated efficacy.
References
- Australian Patent Office. (2022). Patent AU2018201011 detailed certificate.
- World Intellectual Property Organization. (2022). International patent applications related to the same family (WO2019134444).
- U.S. Patent and Trademark Office. (2019). US20190212345 filings related to the patent family.
- PatentScope. (2022). Patent family analysis for chemical and pharmaceutical patents (WIPO).
